News

The proposed indication for Strensiq is for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. anuma is proposed

RVO is a significant cause of vision impairment and a chronic disease that requires early and ongoing management to obtain the best possible vision. The company said that

Humira is designed for the treatment of these adults with an inadequate response to conventional systemic HS therapy. HS, referred to as acne inversa, is a painful, chronic

The Eurostars project "BUPI – a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients" will be managed by Moberg Pharma and includes six

Farydak is the first histone deacetylase (HDAC) inhibitor approved in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication, to treat these patients who received

In this sturdy, NIAAA is working in partnership with XenoPort, a biopharmaceutical company, which will supply gabapentin enacarbil. Around 346 patients will be enrolled in this randomized, double

The Italian biopharmaceutical firm has also filed an application for orphan designation in the US. RTT primarily affects females with an estimated prevalence ranging from 1:10-20,000 females and

The company said that the study initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection.

DPX-Survivac is Immunovaccine’s new T cell activating immunotherapy, while epacadostat (INCB24360) is Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Under the deal, both the firms will co-fund